Status:
COMPLETED
Rejuvant™ Safety and Biomarker Study
Lead Sponsor:
Ponce De Leon Health
Conditions:
Aging Well
Eligibility:
All Genders
45-75 years
Phase:
NA
Brief Summary
In this randomized, double-blind, placebo-controlled trial in adult men ages 45-65 years and postmenopausal women to age 75 years, the anti-inflammatory property of proprietary CaAKG based dietary sup...
Detailed Description
This is a randomized, double-blind, placebo-controlled trial in adult men ages 45-65 years and postmenopausal women up to age 65 years to measure the effect that Rejuvant dietary supplement products h...
Eligibility Criteria
Inclusion
- Men between the ages of 45 and 75 years
- Postmenopausal Women up to age 75 years per EMR. Women should not have had a menstrual period for at least one year prior to enrollment into the study
Exclusion
- Diabetes as determined by the presence of EMR based diagnosis including prescribed any DM medications
- Diagnosed with severe mental illness, substance abuse disorders per EMR
- Diagnosed with congestive heart disease per EMR
- Had a myocardial infarction in the previous year per EMR
- EMR based Diagnosis of any Cancer in the past 5 years
- EMR based diagnosis of morbid obesity or anorexia nervosa
- Hospitalized in the previous 12 months
- Active smoking
Key Trial Info
Start Date :
February 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04821401
Start Date
February 7 2020
End Date
February 14 2022
Last Update
September 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202